Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-12
2006-09-12
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S457000, C548S459000
Reexamination Certificate
active
07105562
ABSTRACT:
The present invention relates to certain sulfonamido-substituted geometrically restricted indolinones of the formula:wherein R1–R12and X are variables defined herein.The sulfonamido-substituted geometrically restricted indolinones of the preferred embodiments of the present invention modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity.Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
REFERENCES:
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5292737 (1994-03-01), Defauw
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 6130238 (2000-10-01), Tang et al.
patent: 6395734 (2002-05-01), Tang et al.
patent: 0 566 226 (1995-08-01), None
patent: WO 91/15495 (1991-10-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 92/22160 (1992-12-01), None
patent: WO 94/03427 (1994-02-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/14808 (1994-07-01), None
Cheng et al., “Syntheses of 6-Substituted Truncated Yuehchukene Analogs,” Australian Journal of Chemistry, vol. 50(4), p. 349-353 (1997).
Chen et al., STN International (2006) HCAPLUS Database, Columbus, OH, Accession No. 1997:452077.
Jellinek et al., “Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor,”Biochemistry, 1994, pp. 10450-10456, vol. 33, American Chemical Society.
Kendall et al., “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor,”Proc. Natl. Acad. Sci. USA, Nov. 1993, pp. 10705-10709, vol. 90.
Kim et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growthin vivo,”Nature, Apr. 29, 1993, pp. 841-844, vol. 362, No. 6423.
Kinsella et al., “Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel,”Experimental Cell Research, 1992, pp. 56-62, vol. 199, No. 1, Academic Press, Inc.
Mariani et al., “Inhibition of angiogensis by FCE 26806, a potent tyrosine kinase inhibitor,”Proc. Am. Assoc. Cancer Res., Mar. 1994, p. 381, vol. 35.
Takano et al., “Inhibition of Angiogenesis by a Novel Diaminoanthraquinone that Inhibits Protein Kinase,”Molecular Biology of the Cell, Oct. 1993, p. 358a, Abstract #2076, vol. 4.
Wright et al., “Inhibition of Angiogenesis In Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032,”Journal of Cellular Physiology, Sep. 1992, pp. 448-457, vol. 152, No. 3.
Cui Jingrong
Tang Peng Cho
Wei Chung Chen
Zhang Fang-Jie
Freistein Andrew B.
Liptak Vincent P.
Shameem Golam M. M.
Sugen Inc.
Zielinski Bryan C.
LandOfFree
Geometrically restricted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Geometrically restricted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Geometrically restricted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3549148